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Human albumin is used for volume expansion and re-
suscitation and to correct hypoalbuminemia [1]. Hypoal-
buminemia is frequent in sepsis and is a strong predictor
of mortality and morbidity [2]. Fluid volume expansion
and resuscitation of the critically ill with albumin has been
recommended by the UK National Institute for Health
and Care Excellence and the Surviving Sepsis Campaign
(grade 2C), although the evidence for these recommenda-
tions is not strong [1,3-8] and use of albumin to correct or
improve hypoalbuminemia remains controversial [7,8]
despite the fact that albumin is safe to use for the critically
ill [8].
Albumin mobilizes polyunsaturated fatty acids (PUFAs)
from the liver and other tissues, and thus enhances the
formation of cytoprotective bioactive lipids – lipoxins,
resolvins and protectins – that, in turn, suppress produc-
tion of proinflammatory prostaglandins, free radicals and
cytokines. The beneficial actions of albumin thus depend
on its ability to mobilize PUFAs and the formation of ad-
equate amounts of lipoxins, resolvins and protectins. For
those who have hepatic and tissue deficiency of PUFAs, al-
bumin fails to mobilize PUFAs and formation of lipoxins,
resolvins and protectins will be inadequate, which may
explain failure of the beneficial actions of albumin in the
critically ill.
Metabolism of polyunsaturated fatty acids and
formation of lipoxins, resolvins and protectins
The cell membrane is rich in PUFAs (arachidonic acid,
eicosapentaenoic acid and docosahexaenoic acid) that give
rise to both proinflammatory prostaglandins, thrombox-
anes and leukotrienes and anti-inflammatory lipoxins,
resolvins and protectins [9] (see Figure 1). Balance be-
tween these mutually antagonistic compounds could de-
termine the final outcome of the disease process [9,10].Correspondence: Undurti@hotmail.com
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unless otherwise stated.Lipoxins, resolvins and protectins reduce infiltration of
leukocytes, suppress inflammation, show neuroprotective
properties, inhibit oxidative stress-induced apoptosis of
cells, inhibit proinflammatory cyclooxygenase-2 expres-
sion and tumor necrosis factor alpha (TNFα) production,
enhance wound healing and promote brain cell survival by
enhancing neuroprotective gene-expression programs
[9-11]. Albumin enhances the formation of lipoxins,
resolvins and protectins that are anti-inflammatory in
nature and facilitate wound healing and resolution of the
disease process [10,11] by mobilizing PUFAs. Hence, in
albumin deficiency states decreased formation of lipoxins,
resolvins and protectins occurs that may increase morbid-
ity and mortality.
Albumin has anti-inflammatory actions
Plasma concentrations of TNFα, interleukin (IL)-6 and
macrophage inflammatory protein-2 were significantly
lower and the IL-10 concentration higher in the
albumin-treated hemorrhagic shock model animals [12].
Hypoalbuminemia thus results in decreased formation
of IL-10 and lipoxins, resolvins and protectins that leads
to increased morbidity and mortality [2]. The amount of
PUFAs stored in the liver could therefore be one variable
that influences formation of lipoxins, resolvins and
protectins. Decreased activity of cyclooxygenases and 5-
lipoxygenase, 12-lipoxygenase, and 15-lipoxygenase con-
cerned with the formation of lipoxins, resolvins and
protectins is yet another variability that contributes to
the controversial responses to albumin therapy reported.
The albumin half-life time is shorter and its transporta-
tion rate is higher in sepsis compared with control indi-
viduals [11], which results in inadequate availability of
albumin to tissues in sepsis.
Tumor necrosis factor alpha induces
hypoalbuminemia and polyunsaturated fatty acid
deficiency
TNFα administration to healthy well-nourished rabbits
produced hypoalbuminemia [13] and endothelial cellsn Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Metabolism of essential fatty acids and their role in inflammation and its resolution. AA, arachidonic acid; A-FABP, adipose-fatty
acid binding protein; ALA, alpha-linolenic acid; DGLA, dihomo-gamma-linolenic acid; DHA, docosahexaenoic acid; eNO, endothelial nitric oxide;
EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; HMGB1, high-mobility group box 1; IL, interleukin; LA, linolenic acid; LT, leukotriene; PG,
prostaglandin; PlGF, placental growth factor; PGI, prostacyclin; PUFA, polyunsaturated fatty acid; ROS, reactive oxygen species; sFlt1, Soluble fms-like
tyrosine kinase 1; TNFα, tumor necrosis factor alpha; TX, thromboxane; VEGF, vascular endothelial growth factor.
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content and developed essential fatty acid deficiency
[14]. These results suggest that enhanced circulating
levels of TNFα and IL-6 seen in sepsis induce hypoalbu-
minemia and PUFA deficiency that leads to decreased
production of lipoxins, resolvins and protectins. Further-
more, both vascular endothelial growth factor and pla-
cental growth factor that are increased in sepsis can be
modulated by lipoxins, resolvins and protectins [15].
Conclusions
Based on the preceding discussion, I propose that PUFAs
need to be administered along with albumin to enhance
formation of lipoxins, resolvins and protectins to derive
the benefit of albumin therapy in the critically ill [16,17].
Beneficial actions of albumin are limited by: availability
of PUFAs in the liver and other tissues; formation ofadequate amounts of lipoxins, resolvins and protectins
from PUFAs; activity of cyclooxygenase and lipoxygenase
enzymes; circulating levels of TNFα and other cytokines
that interfere with the formation of arachidonic acid,
eicosapentaenoic acid and docosahexaenoic acid and in-
duce hypoalbuminemia; enhanced formation of reactive
oxygen species that peroxidize PUFAs and thus reduce
their availability; and formation of proinflammatory
prostaglandins that antagonize actions of lipoxins, resol-
vins and protectins [16,17] (see Figure 1). In view of the
interactions among albumin, PUFAs, free radicals, pros-
taglandins, lipoxins, resolvins and protectins, nitric oxide
(PUFAs and lipoxins enhance endothelial nitric oxide
generation and protect endothelial cells), vascular endo-
thelial growth factor, placental growth factor and cyto-
kines, it is not surprising that albumin infusion alone is
unlikely to be of benefit in sepsis. Hence, albumin needs
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the actions of proinflammatory molecules and restore
homeostasis [16,17].
Adipose-fatty acid binding protein (A-FABP), which
induces insulin resistance and whose levels are increased
in the critically ill [18], is a carrier of fatty acids and is
expressed primarily in adipocytes and macrophages. A-
FABP regulates systemic insulin sensitivity and lipid and
glucose metabolism [19]. Mice deficient in A-FABP are
resistant to the development of hyperinsulinemia, hyper-
glycemia and insulin resistance [18].
A-FABP can be linked to the expression of Toll-like
receptors, macrophage activation, synthesis and release
of proinflammatory cytokines IL-6 and TNFα, activation
of cyclooxygenase-2 expression and eicosanoid synthesis,
events that cause insulin resistance and initiation and
progression of inflammation and sepsis. PUFAs and
lipoxins, resolvins and protectins suppress A-FABP ex-
pression, inhibit macrophage and cyclooxygenase-2 acti-
vation, and decrease production of proinflammatory
cytokines, and thus decrease insulin resistance and re-
solve inflammation and augment recovery from sepsis
[18,19]. Hence, serial measurement of both proinflam-
matory and anti-inflammatory molecules and correlation
of their levels with the progression to or recovery from
(or both) sepsis and other inflammatory processes may
help to predict prognosis in inflammatory conditions
and eventually could lead to the development of new
therapeutic strategies.
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